A CBD-rich cannabis extract reduced inflammation and pain in lab animals in a dose-dependent manner
A supercritical CO2 extract of a CBD-rich cannabis genotype significantly reduced pro-inflammatory cytokines in cell studies and showed dose-dependent anti-inflammatory and analgesic effects in animal models.
Quick Facts
What This Study Found
The CBD-rich cannabis extract (CSFE) significantly reduced TNF-alpha and IL-6 production in LPS-stimulated macrophages at 3, 10, and 30 mcg/ml without cytotoxicity. In animal models, it demonstrated dose-dependent decreases in inflammation and improvements in pain relief.
Key Numbers
62 compounds identified in the extract. Major cannabinoids: CBD (9.75%), CBDA (2.76%), THC (4.40%). Pro-inflammatory cytokine reduction at 3, 10, and 30 mcg/ml concentrations. Significant dose-dependent anti-inflammatory and analgesic effects in animal models.
How They Did This
Chemical characterization of a supercritical CO2 extract of Cannabis sativa genotype CIM-CS-64 using GC-FID, GC-MS, HPLC, HRMS, and NMR. In vitro anti-inflammatory testing in LPS-stimulated macrophages. In vivo inflammation and pain models in small laboratory animals.
Why This Research Matters
Most cannabis pain research focuses on isolated CBD or THC. This study examines a full-spectrum CBD-rich extract with characterized chemical composition, supporting the idea that the entourage effect of multiple cannabis compounds may contribute to therapeutic outcomes.
The Bigger Picture
This study connects rigorous chemical analysis of a specific cannabis genotype with functional testing, providing a model for how future cannabis-based medicine development might proceed with standardized, well-characterized extracts.
What This Study Doesn't Tell Us
Animal study results may not translate to humans. The extract contains THC (4.40%) alongside CBD, so effects cannot be attributed to CBD alone. Specific animal models and doses used in vivo were not detailed in the abstract.
Questions This Raises
- ?How does this full-spectrum extract compare to isolated CBD for pain and inflammation?
- ?Would the 4.40% THC content produce psychoactive effects at therapeutic doses in humans?
- ?Can these results be replicated with other CBD-dominant cannabis genotypes?
Trust & Context
- Key Stat:
- CBD-rich extract reduced TNF-alpha and IL-6 without cytotoxicity
- Evidence Grade:
- Preliminary: preclinical study with in vitro and animal data only, no human testing.
- Study Age:
- Published 2026.
- Original Title:
- Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study.
- Published In:
- Journal of ethnopharmacology, 357, 120856 (2026)
- Authors:
- Singh, Munmun Kumar, Sen, Sumati, Singh, Swati, Aftab, Nashra, Kumar, Birendra, Gupta, Namita, Tandon, Sudeep, Bawankule, Dnyaneshwar Umrao, Verma, Ram Swaroop
- Database ID:
- RTHC-08629
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can CBD-rich cannabis extract reduce inflammation?
In this preclinical study, a CBD-rich extract significantly reduced pro-inflammatory markers TNF-alpha and IL-6 in cell cultures and showed dose-dependent anti-inflammatory effects in animals.
What was in the cannabis extract studied?
The supercritical CO2 extract contained 62 identified compounds, with CBD (9.75%), CBDA (2.76%), and THC (4.40%) as major cannabinoids, plus terpenes like beta-caryophyllene and alpha-bisabolol.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-08629APA
Singh, Munmun Kumar; Sen, Sumati; Singh, Swati; Aftab, Nashra; Kumar, Birendra; Gupta, Namita; Tandon, Sudeep; Bawankule, Dnyaneshwar Umrao; Verma, Ram Swaroop. (2026). Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study.. Journal of ethnopharmacology, 357, 120856. https://doi.org/10.1016/j.jep.2025.120856
MLA
Singh, Munmun Kumar, et al. "Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study.." Journal of ethnopharmacology, 2026. https://doi.org/10.1016/j.jep.2025.120856
RethinkTHC
RethinkTHC Research Database. "Therapeutic potential of cannabidiol-rich Cannabis sativa to..." RTHC-08629. Retrieved from https://rethinkthc.com/research/singh-2026-therapeutic-potential-of-cannabidiolrich
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.